Korean Skincare Brand CLERIVY Launches U.S. Expansion on Amazon

The initial U.S. launch features the Hydrocolloid Pimple Patch and the Microdart Spot Patch. The latter utilizes water-soluble microdarts infused with 7% niacinamide, 3% tranexamic acid, and a vitamin C derivative to address early-stage blemishes. Clinical testing conducted at Cutis Biomedical Research Center indicated that the hydrocolloid variant is suitable for sensitive skin, with participants reporting a 14.5% reduction in visible redness after one week of use.

While the current offerings are classified as cosmetics, the brand is preparing to expand its portfolio in October 2026 with a medicated Microdart Acne Patch. This upcoming product, which has already been listed with the FDA as an OTC monograph drug, features 2% salicylic acid as its active ingredient. Guhada Co., Ltd., the parent company behind CLERIVY, plans to follow these patch releases with a broader range of serums and creams as it establishes a permanent footprint in the U.S. retail landscape.